Application of Asporin in autoimmune dry eye detection reagents or treatment drugs
By using Asporin as a biomarker and target, non-invasive diagnostic reagents and targeted intervention strategies have been developed, solving the challenges of early diagnosis and treatment of autoimmune dry eye disease and achieving highly sensitive diagnosis and effective disease management.
Patent Information
- Application Number
- CN202611578217.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-13
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies are insufficient for the early diagnosis and effective treatment of autoimmune dry eye syndrome (SS-DED) that is non-invasive, easy to operate, highly specific, and sensitive. Existing diagnostic methods, such as lip gland biopsy, serum autoantibody detection, and tear function assessment, suffer from problems such as invasiveness, low positive rate, or poor repeatability.
Using Asporin as a biomarker, we developed a non-invasive detection reagent and used it as a target for intervention by detecting its expression level in lacrimal gland tissue. We used Asporin protein antibodies, primers or probes for detection and inhibited Asporin expression through lentiviral vectors to improve lacrimal gland inflammation.
It enables precise auxiliary diagnosis, disease assessment, and risk screening for SS-DED, significantly increases tear secretion, improves corneal damage, reduces lacrimal gland inflammatory cell infiltration, and lowers inflammatory factor expression, providing highly sensitive diagnostic and potential treatment strategies.
Smart Images

Figure CN123063518A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical and molecular diagnostic technology, and particularly relates to the application of Asporin in an autoimmune dry eye detection reagent or therapeutic drug. Background Technology
[0002] Dry eye syndrome is a common chronic ocular surface disease characterized by insufficient tear secretion, excessive evaporation, or an imbalance in tear composition. Clinically, it is often accompanied by ocular discomfort and / or visual impairment, severely impacting patients' visual quality and daily life. With the widespread use of electronic display devices, the prevalence of dry eye syndrome is continuously rising; epidemiological data shows that the disease affects approximately 5% to 50% of the global population, gradually evolving into a major public health problem threatening public visual health. Sjögren's syndrome (SS) is a chronic inflammatory autoimmune disease characterized by progressive decline in exocrine gland function. SS-related dry eye (SS-DED) is one of its most common initial clinical manifestations. Patients may experience severe dry eye symptoms, and in severe cases, it can lead to visual impairment or even blindness, significantly reducing patients' quality of life.
[0003] Early diagnosis and timely intervention are crucial for improving the prognosis of Sjögren's Syndrome-related dry eye (SS-DED). However, due to the insidious onset and lack of specificity in early symptoms, accurate identification in the early stages of the disease is often difficult in clinical practice. Currently, the clinical diagnostic system for SS-DED mainly relies on a comprehensive assessment using multidimensional examination methods. Lip gland biopsy confirms the diagnosis by observing focal lymphocyte infiltration in the gland through histopathological examination; however, it is an invasive procedure with low patient acceptance and risks of complications such as bleeding and infection, making it unsuitable as a routine screening or dynamic monitoring method. Serum autoantibody testing mainly provides immunological evidence by detecting anti-SSA (Ro) antibodies, anti-SSB (La) antibodies, rheumatoid factor (RF), and antinuclear antibodies (ANA); however, the antibody positivity rate is low in some early-stage patients, leading to false negative results, and these antibodies can also be found in other autoimmune diseases, limiting their specificity. Tear function and ocular surface assessment often employ methods such as the Schirmer tear secretion test, tear film breakup time (BUT) measurement, corneal fluorescein staining score, tear meniscus height measurement, and meibomian gland function imaging to quantitatively assess tear secretion, tear film stability, and the degree of ocular surface damage. However, these examinations are highly dependent on the operator's skill level and the patient's cooperation, are subjective, have poor repeatability, and lack sensitivity for early, mild ocular surface damage, making it difficult to provide early warning of the disease. While salivary flow rate testing and salivary gland imaging examinations (such as salivary gland ultrasound and parotid gland smear) can help reflect salivary gland involvement, they are cumbersome to perform, dependent on imaging equipment and operator experience, and have limited sensitivity for early decline in exocrine gland function.
[0004] Therefore, developing a simple, non-invasive, objective, and highly sensitive early diagnostic technique for SS-DED is of great clinical significance and application value for improving patient prognosis and reducing disease burden. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention provides Asporin as a biomarker for autoimmune dry eye and provides the application of Asporin or its encoding gene as a target in the preparation of products for the prevention, relief, and / or treatment of autoimmune dry eye.
[0006] The technical solution adopted in this invention is: the application of Asporin as a biomarker in the preparation of autoimmune dry eye test reagents.
[0007] Preferably, the detection reagent includes an antibody against Asporin protein, primers for detecting the Asporin gene and / or mRNA, or probes for detecting the Asporin gene and / or mRNA.
[0008] Preferably, the test sample is a lacrimal gland or tear fluid.
[0009] Application of Asporin as a target in the preparation of drugs for autoimmune dry eye.
[0010] This invention provides the application of Asporin or its encoding gene as a target in the prevention, relief, and / or treatment of autoimmune dry eye. It is the first discovery and demonstration that the expression level of the secreted protein Asporin is significantly and abnormally elevated in the minor salivary glands of SS patients and in the lacrimal gland tissue of autoimmune dry eye model animals, and that its expression changes are highly consistent with the severity of the disease. Therefore, by detecting the expression level of Asporin in the biological samples of subjects, the pathological damage state of lacrimal gland tissue can be accurately reflected, which can be used for the auxiliary diagnosis, disease severity assessment, and disease risk screening of autoimmune dry eye. The Asporin protein can be used as a biomarker to prepare reagents or kits for the auxiliary diagnosis of autoimmune dry eye. Furthermore, animal experiments have further verified that by reducing the expression level of Asporin or inhibiting its activity, this invention can effectively increase tear secretion, improve corneal damage, reduce lacrimal gland inflammatory cell infiltration, and reduce the expression level of inflammatory factors in tissues by inhibiting Th17 cell differentiation, thereby achieving the prevention, relief, and / or treatment of autoimmune dry eye and related autoimmune diseases. This invention breaks through the technical bottleneck of existing diagnostic methods that rely on invasive biopsies, and provides a non-invasive, easy-to-operate, highly specific, and highly sensitive biomarker and targeted intervention strategy. It is suitable for large-scale population screening and long-term dynamic monitoring of patients' conditions, and has extremely high clinical application value and industrialization prospects. Attached Figure Description
[0011] Figure 1 Correlation analysis between disease severity in SS patients and asporin expression levels in minor salivary glands;
[0012] Figure 2 Western blot representation of Asporin protein in mouse lacrimal glands;
[0013] Figure 3 Statistical results of relative expression levels of Asporin protein in mouse lacrimal glands;
[0014] Figure 4 Statistical results of relative expression levels of Asporin mRNA in mouse lacrimal glands;
[0015] Figure 5 Partial sequencing peak diagram of recombinant plasmid shASPN-pLKO.1;
[0016] Figure 6 Fluorescence expression in HEK293T cells after serially diluted lentivirus infection;
[0017] Figure 7 Western blot representation of Asporin protein in EL4 lymphocytes after viral treatment;
[0018] Figure 8 Sodium fluorescein staining of mouse ocular surface;
[0019] Figure 9 Scoring of mouse ocular surface fluorescein sodium staining;
[0020] Figure 10 Changes in tear secretion in mice;
[0021] Figure 11 HE staining results of paraffin sections of mouse lacrimal gland tissue;
[0022] Figure 12 Effects of Asporin knockdown on genes related to Th17 cells in mice;
[0023] Figure 13 Effects of Asporin knockdown on Th1-related genes in mice;
[0024] Figure 14 Effects of Asporin knockdown on genes related to mouse Treg cells;
[0025] Figure 15 Representative flow cytometry results of Asporin knockdown inhibiting Th17 cell polarization in mice;
[0026] Figure 16 Asporin knockdown reduced the percentage of Th17 cells in mice. Detailed Implementation
[0027] The embodiments of the present invention will now be described with reference to the accompanying drawings.
[0028] This invention relates to the application of Asporin in diagnostic reagents or therapeutic drugs for autoimmune dry eye. Asporin belongs to the small leucine-rich proteoglycan (SLRP) family. Asporin promotes the continued development of autoimmune dry eye by activating Th17 lymphocytes, exacerbating the infiltration of inflammatory cells in lacrimal gland tissue, and ultimately promoting the development of autoimmune dry eye.
[0029] Currently, early diagnosis of SS-DED lacks highly specific and sensitive non-invasive molecular biomarkers. Existing diagnostic indicators, such as labial gland biopsy, serum autoantibody detection, and tear function assessment, are difficult to accurately reflect disease progression and pathological changes in lacrimal gland tissue due to their invasiveness or low early positive rates. These methods are unsuitable for routine screening and dynamic monitoring, leading to difficulties in early identification and delayed intervention. However, there is a lack of specific molecules that can reflect pathological damage to the lacrimal gland during the development of SS-DED. This invention aims to address these technical problems by providing a novel biomarker for SS-DED. By detecting the expression level of this biomarker in biological samples, it enables auxiliary diagnosis, disease assessment, or screening of SS-DED, providing a new molecular target and technical means for the early diagnosis of SS-DED.
[0030] Asporin can serve as a biomarker for autoimmune dry eye. By utilizing the significantly elevated expression of Asporin in the salivary glands of patients with Sjögren's syndrome and the lacrimal gland tissues of animals with autoimmune dry eye, more accurate and specific auxiliary diagnosis of autoimmune dry eye can be achieved. This overcomes the shortcomings of existing biomarkers, such as insufficient target specificity, limited early diagnostic efficacy, and inability to non-invasively reflect pathological changes in the lacrimal gland. It provides new approaches and technical support for early clinical diagnosis, disease monitoring, and the development of related diagnostic reagents for SS-DED.
[0031] The detection reagent may include antibodies against Asporin protein, active substances capable of binding Asporin protein (such as TGF-β1, BMP-2 or collagen fragments), primers for detecting Asporin gene and / or mRNA (as shown in SEQ ID No. 1 and SEQ ID No. 2), or probes for detecting Asporin gene and / or mRNA.
[0032] In addition, asporin can serve as a target for autoimmune dry eye, and its expression can be knocked down to treat autoimmune dry eye. A lentiviral vector carrying an interfering sequence targeting asporin can effectively inhibit Th17 cell activation; during administration, the lentivirus containing the interfering sequence is injected subconjunctivally (viral titer 1×10⁻⁶). 8 (TU / mL, 10 μL / eye). Experimental results showed that downregulation of Asporin expression in the eye significantly increased tear secretion, improved corneal damage, and alleviated pathological changes in lacrimal gland tissue.
[0033] The technical solution of the present invention will now be described in detail with reference to the accompanying drawings. For experimental methods where the operational steps are not specifically described, the corresponding product instructions shall apply. Unless otherwise specified, the instruments, reagents, and consumables involved in the embodiments can be purchased commercially.
[0034] Male NOD / ShiLtJ (NOD) mice (12 weeks old, weighing 32±1g) and male BALB / c mice (12 weeks old, weighing 25±1g) were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. Animals were housed in an SPF-grade environment at a temperature of 20–25 ℃ and a relative humidity of 50%–60%, with a 12-hour light / dark cycle. Mice had free access to food and water. All animal experiments strictly followed the Tianjin Medical University Guidelines for Laboratory Animal Care and Use and were approved by the Tianjin Medical University Laboratory Animal Ethics Committee.
[0035] Example 1: Asporin as a specific biomarker for SS-DED.
[0036] 1.1 GEO Data Analysis
[0037] Using transcriptomic data of SS patients from the GEO public database, we selected age- and sex-matched minor salivary gland tissue samples from the SS group and the non-SS control group to obtain their standardized transcriptional expression matrix. Based on the gene symbol index, we retrieved the mRNA expression data of Asporin from each group, using the expression level in non-SS patients as a reference, to analyze the transcriptional differences of Asporin in the minor salivary gland tissues of SS patients. Data analysis is as follows: Figure 1 The results showed that the expression level of Asporin in the minor salivary gland tissue of SS patients increased with the severity of the disease, confirming that Asporin can serve as a biomarker for assessing SS and monitoring the degree of disease progression.
[0038] 1.2 Western blot analysis of asporin expression levels in lacrimal gland tissue of SS-DED mice
[0039] SPF-grade NOD / ShiLtJ mice (autoimmune dry eye model group) and BALB / c mice (normal control group) were euthanized by cervical dislocation at week 16. Lacrimal gland tissue was harvested, flash-frozen in liquid nitrogen, and stored at -80 °C for later use. A suitable amount of lacrimal gland tissue was taken, and RIPA lysis buffer containing protease inhibitors and phosphatase inhibitors was added. After homogenization on ice, the tissue was centrifuged, and the supernatant was collected. Protein concentration was determined by the BCA method. Equal amounts of protein samples were separated by SDS-PAGE electrophoresis, transferred to PVDF membranes, blocked with 5% skim milk powder, and incubated overnight at 4 °C with goat anti-rabbit asporin primary antibody. The next day, HRP-labeled rabbit anti-goat secondary antibody was added, and the membrane was incubated at room temperature before ECL chemiluminescence imaging. β-Actin was used as an internal control, and the band gray values were measured using image analysis software. The band gray value results were statistically analyzed as follows: Figure 2 and Figure 3 The results showed that the expression level of Asporin protein in the lacrimal gland tissue of dry eye model mice was significantly increased compared with that of normal mice.
[0040] 1.3 Real-time quantitative PCR (RT-qPCR) detection of asporin expression level in lacrimal gland tissue of SS-DED mice
[0041] RT-qPCR validation experiments were performed using the SteadyPure Rapid RNA Extraction Kit (Code No. AG21023, Aikerui Biotechnology) to extract total RNA from lacrimal gland tissue: ≤10 mg of frozen lacrimal gland tissue was taken, 300 μL of Buffer QLS lysis buffer was added, and the tissue was lysed by high-speed vortexing or repeated pipetting for 3-5 min until complete lysis was achieved; the tissue was centrifuged at 12,000 rpm and 4℃ for 5 min, and the supernatant was collected; an equal volume of 100% ethanol was added, and the tissue was mixed by pipetting and transferred to Quick RNA Mini Columns, and centrifuged at 12,000 rpm at room temperature for 2 min; 700 μL of Buffer QWB (with anhydrous ethanol added at a 3:7 volume ratio) was added for washing, and the tissue was centrifuged at 12,000 rpm for 1 min; the adsorption column was transferred to a new collection tube, and the empty tube was centrifuged at 12,000 rpm for 2 min; 30-50 μL of RNase FreeWater was added, the tissue was incubated at room temperature for 3 min, and the RNA was eluted by centrifugation at 12,000 rpm for 2 min, and stored at -80℃. The extracted total RNA was purified and its concentration determined by NanoDrop, and then digested with DNase I (RNase Free) (Code No. AG12001) to remove genomic DNA contamination. cDNA synthesis was performed using Evo M-MLV reverse transcription reagent premix (for qPCR) (Code No. AG11706, Aikerui Biotechnology). The 10 μL reverse transcription system contained: 2 μL of 5×Evo M-MLV RT Master Mix, 500 ng of total RNA, and RNase-free water to a final volume of 10 μL. The reaction conditions were: incubation at 37°C for 15 min, followed by incubation at 85°C for 5 sec. The resulting cDNA was stored at -20°C for later use. Quantitative real-time PCR was performed using the SYBR Green Pro Taq HS premixed qPCR kit (Code No. AG11701, Aikerui Biotechnology). A 20 μL reaction mixture contained: 10 μL of 2×SYBR Green Pro Taq HS Premix, 2 μL of cDNA template, 0.4 μL of mouse Asporin upstream primer (10 μM) and 0.4 μL of downstream primer (10 μM), with RNase-free water added to a final volume of 20 μL. The two-step reaction program was: 95℃ pre-denaturation for 30 sec; 95℃ denaturation for 5 sec, followed by annealing / extension at 60℃ for 30 sec (fluorescence signal acquisition), for a total of 40 cycles. Melting curves were acquired (95℃ for 15 sec, 60℃ for 1 min, 95℃ for 1 sec). A quantitative real-time amplification system was configured using GAPDH as an internal control gene, and the relative mRNA expression level of Asporin was calculated using the 2^-ΔΔCt method.The Asporin-specific primer pairs used included: upstream primer 5′-ATCCCACAACCAACTAAG-3′ (SEQ ID No. 1); downstream primer 5′-ATTCCCTTGAACGTGTCC-3′ (SEQ ID No. 2).
[0042] Experimental results are as follows Figure 4 As shown, the expression level of Asporin was significantly upregulated in the lacrimal gland tissue of an autoimmune dry eye model mouse. This result confirms that Asporin has good clinical feasibility as a biomarker for autoimmune dry eye.
[0043] Example 2: Asporin as a target of SS-DED
[0044] Asporin knockdown can alleviate the severity of SS-DED. Recombinant lentiviral vectors carrying the Asporin shRNA sequence and lentiviral vectors carrying the nonsense control sequence were resuspended in sterile PBS, and the viral titer was adjusted to 1×10⁻⁶. 8 TU / mL. Twelve-week-old NOD / ShiLtJ mice were randomly assigned to the Asporin knockdown group and the negative control group (control vector group). Healthy BALB / c mice of the same age served as the normal control group. On days 1, 4, and 6, mice in the shAsporin-LV and shControl-LV groups underwent bilateral subconjunctival injections of 10 μL of the corresponding lentivirus suspension in each eye. The normal control group received no treatment. Mice in each group were observed for 28 consecutive days, during which samples were collected at predetermined time points and relevant indicators were measured.
[0045] 2.1 Construction of shRNA lentiviral vector targeting mouse Aspn gene and verification of silencing efficiency
[0046] Based on the mouse Aspn gene sequence, a specific shRNA interference sequence targeting Aspn mRNA and its nonsense control sequence were designed and synthesized. The sense and antisense primers were annealed to form a double-stranded DNA fragment. Simultaneously, the pLKO lentiviral vector was double-digested with restriction endonucleases EcoRI and AgeI, and the linearized vector was recovered by agarose gel electrophoresis. The annealed shRNA product and the linearized vector were ligated with T4 DNA ligase, transformed into DH5α competent cells, and ampicillin-resistant single colonies were picked for colony PCR amplification and Sanger sequencing identification. Large quantities of the correctly sequenced recombinant plasmid and the empty control plasmid were extracted and mixed with the lentiviral packaging plasmid pSPAX2 and the envelope plasmid pMD2.G at a 1:1:1 molar ratio, and co-transfected into 293T cells using LipoFiter transfection reagent for lentiviral packaging. Cell culture supernatants were collected at 48 h and 72 h post-transfection. After filtration through a 0.45 μm filter to remove cell debris, viral particles were concentrated using the PEG 8000 / NaCl precipitation method. 293T cells were then infected using a serial dilution method, and viral titers were calculated by observing Zsgreen expression under fluorescence microscopy. EL4 cells were further infected with an MOI of 10, with polybrene added to promote infection. Cell lysates were collected after 48 h for Western blot analysis. Results are as follows: Figure 5 As shown, the recombinant plasmid sequence was verified to be correct by Sanger sequencing. Figure 6 As shown, the viral titer reached 1×10⁻⁶. 8 TU / mL. For example... Figure 7 As shown, after infection with EL4 cells, Western blot analysis revealed that ASPN protein expression was significantly downregulated. These results confirm the successful construction of the Asporin gene silencing vector, laying the foundation for subsequent research.
[0047] 2.2 Corneal fluorescein staining and scoring
[0048] Mice were anesthetized by intraperitoneal injection of tribromoethanol (dose calculated based on 240 μL / 10 g body weight). After anesthesia took effect, compound tropicamide was instilled into both conjunctival sacs to fully dilate the pupils, followed by instillation of 0.5 μL of 2% sodium fluorescein. The mice were encouraged to blink to ensure even distribution of the sodium fluorescein. After 3 minutes of rest, the corneal epithelial defects were assessed and photographed under cobalt blue light using a slit-lamp microscope. The cornea was divided into four quadrants for independent scoring, and the scores from each quadrant were summed to obtain the total score for the eye (scoring criteria are shown in Table 1). Results are as follows: Figure 8 As shown, the control group exhibited significant corneal epithelial defects, which progressively worsened with disease progression; while the Asporin knockdown group showed significantly reduced corneal fluorescein staining and a markedly limited extent of epithelial defects. Corneal staining scores are as follows: Figure 9As shown, the Asporin knockdown group had a significantly lower score than the control vector group, indicating that silencing Asporin can effectively maintain the integrity of the corneal epithelium.
[0049] Table 1. Scoring Criteria for Sodium Fluorescein Staining of Mouse Corneal Epithelium
[0050]
[0051] 2.3 Measurement of tear secretion
[0052] like Figure 10 As shown, the phenol red cotton thread test results further revealed that, compared with normal BALB / c mice, the tear secretion in the NOD model group was significantly decreased; after LV-shAsporin intervention, the tear secretion in NOD mice significantly increased compared with the LV-shCtrl group (P<0.05). These results indicate that local silencing of Asporin can significantly improve corneal damage and tear secretion function in NOD mice, suggesting that targeted inhibition of Asporin has potential therapeutic value for autoimmune dry eye.
[0053] 2.4 Histopathological observation of the lacrimal gland
[0054] To further evaluate the histological changes in the lacrimal gland, the right lacrimal gland of each group of mice was harvested at week 4 after the intervention. After fixation in 4% paraformaldehyde, paraffin embedding, and H&E staining, the lacrimal gland acinar structure and inflammatory cell infiltration were observed under a light microscope. Results are as follows: Figure 11 As shown: Compared with the normal group, the lacrimal gland tissue of the control vector group showed a large number of focal lymphocyte infiltrations, obvious destruction of acinar structure, and extensive atrophy of acinar cells. In contrast, the area of lymphocyte infiltration in the lacrimal gland of the Asporin knockdown group was significantly reduced, the degree of acinar atrophy was significantly reduced, and the glandular structure was relatively intact compared with the control vector group. This suggests that targeted silencing of Asporin can effectively alleviate local inflammatory response and tissue damage in the lacrimal gland of NOD dry eye model mice.
[0055] 2.5 Effects of Asporin knockdown on mouse CD4+ T lymphocyte subsets
[0056] To investigate the regulatory effect of asporin silencing on the polarization of CD4+ T cell subsets in the lacrimal gland, lacrimal gland tissues from mice in each group were collected after 4 weeks of intervention. RT-qPCR was used to detect the mRNA expression levels of characteristic transcription factors and effector molecules of Th1, Th17, and Treg cells. Results are as follows: Figure 12 The results showed that, compared with the control vector group, the transcription levels of Th17 cell-related genes Rorc and Il17 in lacrimal gland tissue were significantly downregulated in the Asporin knockdown group. Meanwhile, the transcription levels of Th1 cell-related genes Ifng and Tbx21 were significantly downregulated. Figure 13 ) and Treg cell-related genes Il10, Foxp3 ( Figure 14 There was no statistically significant difference in the mRNA expression levels of Asporin between the two groups (the relevant primer sequences used are shown in Table 2). These results indicate that local silencing of the Asporin gene in the eye can selectively inhibit the expression of genes related to Th17 cell differentiation and effector function in the lacrimal gland, while having no significant effect on the gene expression profiles of Th1 and Treg cell subsets. This suggests that Asporin may participate in lacrimal gland tissue immune damage during the pathogenesis of SS-DED by specifically regulating the Th17 polarization pathway.
[0057] Table 2. Primer sequences for mouse qRT-PCR
[0058]
[0059] 2.6 Effect of Asporin knockdown on the proportion of Th17 lymphocytes in mice
[0060] Four weeks after intervention, mice were euthanized by cervical dislocation. Cervical lymph nodes were isolated and gently ground in pre-cooled culture medium through a 70 μm cell sieve. Single-cell suspensions were obtained after filtration through a 70 μm filter. After in vitro stimulation, surface staining was performed with fluorescein-conjugated anti-mouse CD4 antibody, followed by incubation at 4°C in the dark. After fixation and membrane perforation, intracellular staining was performed with fluorescein-labeled anti-IL-17 antibody. After washing with PBS to remove unbound antibodies, the proportion of Th17 (CD4+IL-17+) cells in each group was detected by flow cytometry. Results are as follows: Figure 15 and 16 As shown, compared with the control vector group, the proportion of Th17 cells in the Asporin knockdown group mice was significantly reduced. This result further confirms that Asporin mediates the occurrence and development of SS-DED through Th17 cell function regulation.
[0061] Based on the above in vitro and in vivo experimental results, Asporin has dual application value in the occurrence and development of SS-DED. On the one hand, as a novel biomarker, Asporin is significantly highly expressed in the lacrimal gland tissue of SS-DED model mice and the salivary glands of SS patients, and its expression level is positively correlated with the severity of the disease. Therefore, the detection of Asporin expression levels in ex vivo samples can be used for auxiliary diagnosis, disease assessment, and risk screening of SS-DED. On the other hand, as a potential therapeutic target, targeted silencing of Asporin can significantly improve the clinical manifestations of dry eye in NOD mice, manifested as a significant increase in tear secretion, a significant reduction in corneal epithelial damage, and a decrease in focal lymphocyte infiltration in lacrimal gland tissue. Further analysis of lacrimal gland and lymphoid tissue after in vivo treatment showed that Asporin expression inhibition can selectively downregulate the transcriptional levels of Th17 characteristic genes such as Rorc and Il17, and inhibit the proportion of Th17 subsets, while having no significant effect on the expression of Th1 and Treg cell-related genes or cell proportions. The above results suggest that Asporin is not only a specific molecular marker reflecting the degree of pathological damage in SS-DED, but also a key functional molecule mediating lacrimal gland inflammation and Th17 immune response. Detection reagents and targeted intervention strategies developed around Asporin have significant clinical translational value and industrialization prospects.
[0062] The embodiments of the present invention have been described in detail above. However, the description is only a preferred embodiment of the present invention and should not be considered as limiting the scope of the present invention. All equivalent changes and improvements made based on the scope of the present invention should still fall within the patent coverage of the present invention.
Claims
1. Application of Asporin as a biomarker in the preparation of reagents for detecting autoimmune dry eye syndrome.
2. The application according to claim 1, characterized in that: The detection reagents include antibodies against Asporin protein, primers for detecting the Asporin gene and / or mRNA, or probes for detecting the Asporin gene and / or mRNA.
3. The application according to claim 1, characterized in that: The test sample is the lacrimal gland or tear fluid.
4. Application of Asporin as a target in the preparation of drugs for autoimmune dry eye syndrome.
